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Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hema-
topoietic stem cell transplantation (HSCT). Measures developed that have signiﬁcantly reduced GVHD were
also frequently associated with an increased risk of relapse. GVHD and graft-versus-tumor (GVT) effects are
tightly linked, and balance between both reactions is difﬁcult to achieve. To have an impact on the outcome
and quality of life after HSCT, improvements in current strategies to prevent and treat GVHD while preserving
the GVT effect are clearly needed. Sirolimus (rapamycin) is a lipophilic macrocytic lactone with immuno-
suppressive, antitumor, and antiviral properties. Because of its multiple modes of activities, it is being
increasingly used in the management of GVHD. This review aims to summarize its mechanisms of action and
potential advantages over other immunosuppressors and to analyze the most relevant studies investigating
its role in both prevention and treatment of GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Graft-versus-host disease (GVHD) either acute or chronic
remains a major cause of morbidity and mortality after
allogeneic hematopoietic stem cell transplantations (HSCT)
and has a negative impact on quality of life. Despite standard
prophylaxis using calcineurin inhibitor (CNI)-based regi-
mens, grade II to IV acute GVHD (aGVHD) still develops in
30% to 50% of matched sibling transplantations and in 40% to
70% of matched unrelated donor (MUD) transplantations,
whereas chronic GVHD (cGVHD) develops in up to 50% and
70% of related and unrelated transplantations, respectively.
Improvements of current strategies to prevent and treat
GVHD while preserving the graft-versus-tumor (GVT) effect
are required in order to improve the outcomes of allogeneic
transplantations. Because of its multifaceted activities, siro-
limus is an appealing drug for the management of GVHD.
Sirolimus (rapamycin) is a lipophilic macrocytic lactone
with immunosuppressive properties. As a result of its
successful use alone and in combination with CNIs for
prevention of allograft rejection after solid organ trans-
plantation [1,2], it has recentlyemerged in themanagementof
GVHD. Its unique properties give it potential advantages over
other immunosuppressive agents currently in use. These
advantages include (1) immunosuppressive action through
T cell inhibition while promoting CD4þCD25þFoxP3þ regu-
latory T cells (Tregs), a T cell population involved in GVT
reaction, (2) inhibition of antigen presentation and dendritic
cell maturation, (3) antiﬁbrotic properties, (4) antineoplastic
activity, (5) antiviral activity, (6) synergistic action whenedgments on page 20.
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12.06.020combined to tacrolimus, and (7) minimal nephrotoxicity and
hepatotoxicity.
Sirolimus, structurally similar to tacrolimus, binds to the
same family of intracellular FK-506 binding proteins but at
a distinct site. It forms complexes that inhibit the mamma-
lian target of rapamycin (mTOR), a protein kinase that
regulates mRNA translation and protein synthesis, an
essential step in cell division and proliferation. It also inhibits
cell cycle entry in response to interleukin-2 (IL-2), leading to
T cell apoptosis [3]. Despite the theoretical competition for
FK 506-binding proteins binding sites between sirolimus and
CNIs, they seem to work synergistically, because sirolimus
does not interact with calcineurin or its downstream effec-
tors [3,4]. The combination of sirolimus and tacrolimus,
when compared with combination of sirolimus and cyclo-
sporine, has demonstrated higher efﬁcacy and lower toxicity
proﬁle [5-7].
The unique actions of sirolimus are the speciﬁc inhibition
of CD8þ T cell proliferation [8] and dendritic cell activity [9-
14]. In contrast to CNI, sirolimus promotes the generation of
Tregs [15,16]. Because Tregs process is IL-2-dependent, it is
blocked by CNIs. Sirolimus demonstrates its antiﬁbrotic
effect by reducing collagen mRNA levels, by inhibiting
extracellular matrix deposition and ﬁbrogenesis, and by
inhibition of platelet-derived growth factor-induced ﬁbro-
blast proliferation [17-20]. This could provide a signiﬁcant
additional advantage in the treatment of cGVHD with scle-
rodermatous features and for bronchiolitis obliterans.
Sirolimus demonstrates antineoplastic properties. In
hematological malignancies, sirolimus has shown antineo-
plastic activity against myelodysplastic syndrome [21], acute
myeloid leukemia (AML), and chronic myeloid leukemia [22]
especially with FLT3 or BCR-ABL mutations [23,24] and
T-acute lymphoblastic leukemia [25]. This antineoplastic
activity provides a major advantage for the use of sirolimus
in the management of GVHD, because of the commonTransplantation.
Table 1
Sirolimus in GVHD Prophylaxis
COH [52] DFCI [53]
No. of patients 85 83
Low risk 54% 0%
High risk 46% 100%
Donor type
MRD 100% 64%
MUD 0% 36%
Stem cell source
PBSC 94% 100%
BM 6% 0%
Conditioning
Flu/Mel 54% 0%
TBI-VP16 33% 0%
Bu/Cy 13% 0%
TBI-Cy 0% 100%
Engraftment
Neutrophils 15 days 14 days
Platelets 12 days
aGVHD
Median onset 19 days 21 days
Grade II-IV 43% 20.5%
Grade III-IV 15% 4.8%
cGVHD
Total 51% 59.1%
Limited 29%
Extensive 71%
Outcome
Median FU 26 mos 33.5 mos
OS 2 year 66% 72.2%
DFS 2 year 58% 68.5%
Relapse 2 year 34% 16.2%
NRM 100 days 4.8% 4.8%
NRM 2 year 10.2%
Toxicity
DAH/IPS 2.4% 1.2%
CMV infection 25% 3%
TMA 19% 7%
VOD 2.4% 7%
COH indicates City of Hope; DFCI, Dana Farber Cancer Institute; MRD,
matched related donors; MUD, matched unrelated donor; PBSC, peripheral
blood stem cells; BM, bone marrow; Flu/Mel, ﬂudarabine/melphalan; TBI-
VP16, total body irradiation and etoposide; Bu/Cy, busulfan and cyclo-
phosphamide; TBI-Cy, total body irradiation-cyclophosphamide; aGVHD,
acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease;
FU, follow-up; OS, overall survival; DFS, disease-free survival; NRM, non-
relapse mortality; DAH, diffuse alveolar hemorrhage; IPS, interstitial
pneumonitis; CMV, cytomegalovirus; TMA, thrombotic microangiopathy;
VOD, veno-occlusive disease.
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disease relapse posttransplantation.
Sirolimus also exerts antiviral actions, particularly against
cytomegalovirus (CMV) [26] and EpsteineBarr virus [27,28].
It inhibits tumor growth in patients with EpsteineBarr virus-
related Burkitt’s lymphoma [29] and has also been successful
in the treatment of posttransplantation lymphoproliferative
disease [30-32].
Despite its signiﬁcant advantages over CNIs, sirolimus has
speciﬁc adverse reactions requiring careful monitoring.
Reversible cytopenias [33] and hyperlipidemia [34] are the
most commonly reported, occurring in 40% and 61% of renal
transplantation recipients, respectively [33,35,36]. Sirolimus
mayalso impairwound healing [37] because of its antiﬁbrotic
effect [38]. Other toxicities include interstitial pneumonitis
[39], cutaneous reactions, and mucosal ulcers [40,41].
When sirolimus is combined with CNIs, increased inci-
dences of transplantation-associated thrombotic micro-
angiopathy (TMA) and possibly veno-occlusive disease
(VOD) have been observed [42]. Sirolimus may promote TMA
via direct endothelial cell damage or potentiation of CNIs
effects [43,44]. However, TMA related to sirolimus mono-
therapy has been less commonly reported [45,46]. In
contrast to CNIs, no TMA was observed when sirolimus was
combined with mycophenolate mofetyl (MMF) for GVHD
prophylaxis. Sirolimus is not neurotoxic and seems to have
minimal renal toxicity [47-49], potentiating CNI-induced
nephrotoxicity rather than inducing it [50].
This review aims to summarize the most relevant studies
investigating the impact of sirolimus on the management of
GVHD after HSCT in order to better deﬁne its role and opti-
mize its use.
ROLE OF SIROLIMUS IN GVHD PROPHYLAXIS
The standard of care for aGVHD prophylaxis remains
a combination of CNIs with methotrexate (MTX) resulting in
grade II to IV aGVHD incidences of 30% to 50% in matched-
related-donor (MRD) and 40% to 70% after MUD trans-
plantations. Regimens combining sirolimus with a CNI and
MTX, as triple therapy, have not been shown to be superior to
a regimen of sirolimus with a CNI [51]. Moreover, the
combination of sirolimus with tacrolimus has been shown
more efﬁcacious and less toxic than sirolimus with cyclo-
sporine A (CSA) [5-7]. Therefore, we elected in this review to
focus on studies examining the combination of sirolimus and
tacrolimus without MTX. These retrospective studies were
conducted by Rodriguez et al. [52] at City of Hope (COH)
National Medical Center, by Cutler et al. [53] at Dana-Farber
Cancer Institute (DFCI) and by Rosenbeck et al. [54] at Indi-
ana University. We also included the study by Schleuning
et al. [55], the only study investigating the combination of
sirolimus and MMF without CNI.
TACROLIMUS e SIROLIMUS PROPHYLAXIS
Patients’ characteristics of the2major studies analyzing the
combination of sirolimus/tacrolimus for GHVDprophylaxis are
shown in Table 1 [52,53]. Both studies used the same regimen.
Sirolimus and tacrolimus were started on day -3 with a siroli-
mus loading dose of 12 mg for 1 day followed by 4mg daily to
target a serum level between 3 and 12 ng/mL. Tacrolimus
administration targeteda serumlevelbetween5and10ng/mL.
Immunosuppression taper began on day þ100. Incidences of
grade II to IV aGVHD were 20.5% and 43% and grade III to IV
were 4.8% and 15%. Unexpectedly, there was a statistically
insigniﬁcant higher probability of aGVHD for patientsconditioned with busulfan and cyclophosphamide when
compared to total body irradiation (TBI)/etoposide (VP16) or
ﬂudarabine/melphalan. The incidences of cGVHD were 51%
and 59% in the DFCI and COH studies, respectively.
Results were similar at DFCI for related and unrelated
transplantations. Overall survival (OS), disease-free survival
(DFS), relapse, and nonrelapse mortality (NRM) are shown in
Table 1. The major cause of treatment failure in both studies
was relapse. CMV reactivation in the DFCI study was reduced
to 3%, which supports the hypothesis of sirolimus’ antiviral
activity. Another explanation could be the lower incidence of
aGVHD at DFCI, a known risk factor for CMV reactivation and
infection. No anti-CMV beneﬁt was observed at COH, where
the incidence of aGVHD was higher. The protective role of
sirolimus for CMV reactivation and viral infection prevention
requires prospective evaluation in a comparable cohort of
patients to be conclusive.
The most common toxicities are shown in Table 1. In the
COH study, 4.7% of patients stopped tacrolimus and/or siro-
limus before day þ30 due to toxicity, which could have
contributed to the higher rate of aGVHD. As expected, the
incidence of TMA was high. The COH team discontinued
tacrolimus in 50% and/or sirolimus in 85%, while the DFCI
reduced or discontinued tacrolimus butmaintained sirolimus
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study, the busulfan armwas closed early to accrual as a result
of a higher TMA incidence. The risk factors associated with
TMAwere myeloablative regimens and aGVHD. Diffuse alve-
olar hemorrhagewas observed in 1 case (1.2%) at theDFCI and
was not fatal, whereas there were 2 cases at the COH (2.5%),
both fatal. VOD was observed in 7 patients (8.4%) at the DFCI
and was the cause of death in 4 patients, 2 of whom were
exposed to gemtuzumab before HSCT. It was observed in only
2 patients (2.4%) at the COH.
The study conducted by Rosenbeck et al. [54] compared
the combination of sirolimus and tacrolimus þ/ ATG to the
combination of CNI and MTX for related and unrelated
transplantations. Datawere collected from106 patients, 59 in
the sirolimus group and 47 in the MTX group. All patients
receivedmyeloablative conditioning, either TBI andbusulfan-
based regimens. Peripheral blood stem cells (PBSCs) were the
main source of stem cells. There was a greater use of antith-
ymocyte globulin (ATG) in the sirolimus group (48%)
compared to the MTX group (2%) (P ¼ .001). Sirolimus and
tacrolimus administration dose and schedules were the same
as in the 2 previous studies (COH and DFCI), and MTX was
given at standard doses. The incidence of aGVHDwas lower in
the sirolimus group (grade II-IV ¼ 18.6%; grade III-IV ¼ 5.1%)
than in the MTX-CNI group (grade II-IV ¼ 48.9%, P ¼ .001;
grade III-IV ¼ 17%, P ¼ .45). The hazard for aGVHD was 5.8
times higher for MTX/CNI combination (P ¼ .002). A possible
anti-aGVHD effect of ATG cannot be excluded. The incidence
and severity of aGVHDwas not affected bydonor type orHLA-
mismatches. Despite a more frequent use of ATG in the siro-
limus group, the incidence of cGVHD was not signiﬁcantly
different between the 2 groups (40.4% vs 41.9% for the siroli-
mus and MTX groups, respectively; P ¼ .89). Survival at
day þ30 and þ100 were not statistically different. There was
also no difference in relapse-free-survival (RFS) (P¼ .13). ATG
did not seem to inﬂuence the relapse rates.
A higher rate of VOD was observed in patients exposed to
sirolimus (20.3%) when compared to the MTX group (4.2%,
P ¼ .15). The sirolimus mean serum trough levels were
signiﬁcantly higher in patients who developed VOD, which
again underlines the importance of close blood level moni-
toring. The incidence of TMA in the sirolimus group (10.2%)
was not statistically different from the MTX group (4.3%, P ¼
.296). In patients receiving sirolimus, the majority of viral
infections occurred in those who received ATG. There was no
signiﬁcant impact of the prophylactic regimen on cGVHD,
transplantation-related toxicities, and survival by multivar-
iate analysis. The reduction in aGVHD incidence in the siro-
limus group was offset by the high rate of VOD and viral
infection, resulting in no signiﬁcant survival difference. This
study suggests that there is no advantage to add ATG to the
sirolimus-tacrolimus combination.
Despite its theoretical advantages over other immuno-
suppressive drugs, few studies have addressed what should
be the role of sirolimus in GVHD prophylaxis. Most of the
evidence available is extracted from retrospective studies.
Despite their limitations, several important points can be
underlined. When combining sirolimus to a CNI, tacrolimus
should be selected over CSA to minimize toxicity. There is no
advantage to add MTX to the sirolimus-tacrolimus combi-
nation. Incidence and severity of aGVHD are not affected by
donor type (MRD or MUD) and compare favorably to the
MTX-CSA combination, whereas there seems to be no
signiﬁcant impact on cGVHD incidence. This is rather
surprising considering that aGVHD is a signiﬁcant risk factorfor cGVHD. Although cGVHD is traditionally linked to graft-
versus-leukemia (GVL) effect and disease control, it is also
one of the major complications affecting quality of life in
long-term survivors when extensive. Strategies to limit the
severity of cGVHD are clearly needed. The impact of siroli-
mus-tacrolimus prophylaxis on cGVHD severity and target
organ involvement speciﬁcity remains unanswered and
represents a crucial issue for its future development. The
major complications associated with the combination are
TMA and VOD. To minimize their risk, careful monitoring is
required and target serum levels between 5 to 10 ng/mL for
both medications, is recommended. Tacrolimus and siroli-
mus regimen for GVHD prophylaxis is currently being tested
against tacrolimus andMTX in a randomized phase III trial in
MRD recipients by the BoneMarrow Transplant Clinical trials
Network (BMT CTN) [56]. The results of this important study
will deﬁne the role of this novel combination in GVHD
prophylaxis and help answer some of these questions.
CNI-FREE PROPHYLAXIS (SIROLIMUS e MMF)
Onlyone studybySchleuninget al. [55] investigated aCNI-
free GVHD prophylaxis regimen with sirolimus combined
with MMF and ATG for patients with high-risk leukemia. The
rationale was to test the feasibility of a CNI-free GVHD
prophylaxis to avoid CNI toxicity and interference with GVL
effect through inhibition of Tregs. The goal was also to take
advantage of the antileukemic activity of sirolimus to bridge
the time between conditioning and occurrence of the GVL
effect.
The study retrospectively analyzed data from 15 patients
with high-risk leukemia. Three patients had T-acute lympho-
blastic leukemia (1 refractory and 2 in relapse after allogeneic
transplantation), 10 patients had AML with FLT3 or mixed-
lineage leukemia (MLL) mutations, and 2 patients had chronic
myeloid leukemia in refractory blast crisis. Only 5 patients
were in remission. All but 1 patient received PBSCs. Donors
were siblings in40%andmatchedunrelated in60%.All patients
received a reduced-intensity conditioning (RIC) designed for
patients with high-risk leukemia, the ﬂudarabine, amsacrine,
and cytosine arabinoside (FLAMSA)-RIC protocol. Sirolimus
was administered from day -1 at a dose of 2 mg twice daily to
target serum levels between 5 and 10 ng/mL. In the absence of
GVHD, tapering of sirolimus started on day þ60 and ended by
day þ90. MMF was administered at a dose of 1,000 mg twice
daily and stopped on dayþ50. ATGwas given to patients with
myeloidmalignancies (80%). The treatment plan also included
the administration of escalating doses of donor lymphocyte
infusions (DLIs) starting on day þ120.
All evaluable patients achieved complete chimerism by
day þ30. The incidence of grade II to IV aGVHD was 22.5%,
whereas the incidence of de novo cGVHD was 30%. Patients
mostly presented with skin and oral mucosa cGVHD. The
incidence of aGVHD was lower, whereas cGVHD incidence
was comparable to previously reported results by the same
team for similar patients and conditioning regimens but
using CSA, MMF, and ATG as GVHD prophylaxis [57,58].
At 1 year, OS was 72%, DFS was 67%, relapse rate 23%, and
NRM was 14%. Five patients (50%) received DLIs. The low
NRM reﬂects the excellent tolerability. The low relapse rate
in this high-risk cohort may suggest an antileukemic activity
of sirolimus. Furthermore, this GVHD prophylaxis regimen
may provide an excellent platform for adjuvant immuno-
therapy, as 50% of patients surviving by day þ120 could
receive DLIs compared to 24% in earlier FLAMSA studies
[57,58]. With regard to toxicity, no renal impairment, TMA, or
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who were seropositive had their CMV reactivated.
Although provocative, these results need to be conﬁrmed
in a prospective study comparing sirolimus-MMF-ATG GVHD
prophylaxis to a CNI-MMF-ATG regimen, in patients with
high-risk leukemia undergoing FLAMSA-RIC transplantation.
If the sirolimus-based regimen proves to be superior, it
would provide evidence for its antileukemic activity and for
Tregs’ function preservation when compared to CNI-based
GVHD prophylaxis. It would also help deﬁne the ground for
posttransplantation immunotherapy in a RIC setting.
SIROLIMUS AS PRIMARY THERAPY FOR aGVHD
Only one study thus far has investigated the role of siro-
limus as primary therapy for aGVHD [59]. This retrospective
study included 32 patients with aGVHD: 4 (13%) grade I, 24
(75%) grade II, and 4 (13%) grade III. No grade IV aGVHD was
included. Organ involvement was skin, the gastrointestinal
(GI) tract, and liver in 53%, 66%, and 16%, respectively. All
cases but one were histologically proven. Sirolimus was
chosen as ﬁrst-line treatment, either because of older age
(median 60 years old), to avoid steroid toxicity, or due to
activemalignancy at time of transplantation (72%were not in
remission at HSCT).
GVHD prophylaxis regimen consisted of tacrolimus-MTX
in 91% and tacrolimus-MMF in 9% of patients. MMF and
tacrolimus were continued in all patients, but the latter was
reduced to target a serum level between 3 and 7 ng /mL after
the initiation of sirolimus to reduce the incidence of TMA. A
median loading dose of 6 mg of sirolimus was administered
to achieve and then maintain serum levels between 4 and 12
ng/mL. Therapeutic levels were attained in all cases,
including those with GI involvement.
Sixteen patients (50%) achieved complete response with
front-line sirolimus without requiring a second-line treat-
ment. Of these, 2 patients had aGVHD recurrence 7 and 12
weeks after initial complete response, which resolved in
both with the addition of prednisone 0.2 to 0.5 mg/kg. Organ
involvement and aGVHD severity were not signiﬁcantly
associated with response to sirolimus. The median time to
initial overall response was 7 days, whereas median time to
complete response was 14 days. The remaining 16 patients,
who were refractory to sirolimus alone, received prednisone
at a median dose of 0.5 mg/kg (range, 0.2-1 mg/kg). Reso-
lution of aGVHD was observed in 12 patients. Chronic GVHD
developed in 17 patients (55%), with a maximal National
Institutes of Health (NIH) score of mild in 5 patients,
moderate in 9 patients, and severe in 3 patients. Median
follow-up was 16 months. The 1-year OS, RFS, relapse rate.
and NRM, were 56%, 37%, 37%, and 20%, respectively. None of
the patients who achieved complete responsewith sirolimus
alone died in remission, compared to 33% of those with
complete response to sirolimus/prednisone and 50% of those
with persistent aGVHD. Toxicities included TMA in 3 patients
that resolved completely with tacrolimus dose reduction,
VOD in 1 patient, and CMV reactivation in 9 of 23 seroposi-
tive patients. The complete response rate after therapy with
sirolimus alone (50%) was retrospectively compared to the
complete response rate after 1 mg/kg prednisone therapy in
a matched cohort of 32 patients from the same center (59%)
and found no statistical difference (P ¼ .47).
Despite the retrospective nature of this study and small
patient numbers, it is interesting to note that sirolimus could
be an alternative to ﬁrst-line corticosteroid treatment in
limited-stage (grade I-II) aGVHD requiring systemic therapy.Because there were few patients with grade III disease, it
would be premature to extrapolate these results to more
severe forms of aGVHD. It is also noteworthy that absorption
of sirolimus was adequate with therapeutic serum levels
achieved even in GI GVHD. The role of sirolimus in aGVHD
treatment should be prospectively studied and compared to
the standard of care. The principal advantages would be its
steroid-sparing effect in susceptible patients and its anti-
tumor potential in high-risk diseases.THERAPY OF STEROID-REFRACTORY aGVHD
Acute GVHD refractory to steroid therapy or steroid
dependent remains a major problem. Steroid treatment for
aGVHD yields a 25% to 40% complete response rate in
patients with grade II to IV aGVHD. Although clinical
improvement occurs in 50% of patients, long-lasting
responses to steroids are seen only in approximately one-
third. Therefore, two-thirds will require additional therapy.
Prognosis remains dismal for those patients not responding
to ﬁrst-line treatment, with a 1-year survival below 30%.
There are no speciﬁc guidelines for the treatment of steroid-
refractory GVHD, and the chosen therapy is based more on
institution preference than proven efﬁcacy.
Ghez et al. [60], and Hoda et al. [61] investigated retro-
spectively the role of sirolimus in steroid refractory aGVHD.
Both studies are summarized in Table 2. All patients
remained on current immunosuppressive therapy for aGVHD
when sirolimuswas initiated. Ghez et al. [60] used 2mg/kg of
methyl prednisone (MP), considered the standard of care for
ﬁrst-line aGVHD treatment, whereas Hoda et al. [61] used
lower doses. Hoda et al. [61] started sirolimus at a median
loading dose of 6 mg for 1 day in 56% of patients followed by
a daily dose of 1 to 2 mg with target levels of 4 to 12 ng/mL.
Ghez et al. [60] used a loading dose of 2 to 4mg/m2 for 5 days
in all patients, followed by 2 to 4 mg/day with target levels of
7 to 13 ng/mL. This difference possibly explains the outcome:
complete response rates were 44% for Hoda et al. [61] and
86% for Ghez et al. [60] with a median of 8 days to complete
response in the latter study. In the Hoda et al. [61] study,
complete response was observed across different GVHD
grades and organs. The organ-speciﬁc complete response
rate was 31% for skin, 45% for GI, and 50% for liver. The GVHD
grade-speciﬁc complete responses were 50% for grades I to II,
50% for grade III, and 25% for grade IV, which were not
statistically different (P ¼ .054). Patients experiencing GVHD
ﬂare after sirolimus taper achieved a second complete
response with reinitiation of sirolimus. Finally, deﬁnitive
control of GVHD was observed in 72% in the Ghez et al. [60]
study compared to 32% for the Hoda et al. [61] study. Chronic
GVHD incidence was similar in both studies (42% and 44%).
Sirolimus levels conﬁrmed adequate intestinal absorption
even in patients with GI GVHD and bleeding.
Hoda et al. [61] demonstrated the successful role of
sirolimus in steroid taper. Forty-one percent of patients were
able to reduce MP below 20 mg/day, and complete MP
discontinuation was achieved in 17%. However, discontinu-
ing all immunosuppression was only possible in 4%. TMA
incidence was very high and occurred in 21% to 45% of
patients. The higher incidence was observed by Ghez et al.
[60] and may be related to the use of CSA, as opposed to
tacrolimus. Interestingly, TMA resolved in half of the patients
by switching from CSA to tacrolimus or MMF and persisted in
the other half therefore requiring discontinuation of siroli-
mus. Hoda et al. [61] had a different approach in managing
Table 2
Sirolimus for Refractory aGVHD
Study Ghez [60] Hoda [61]
No. of patients 22 34
Conditioning
Myeloablative 15 (68%) 32 (94%)
RIC 7 (32%) 2 (6%)
Donor
MRD 8 (36%) 12 (35%)
URD 14 (64%) 22 (65%)
MUD 13 (59%) 25 (74%)
MMUD 9 (41%) 9 (26%)
Stem cell source
PBSC 50% 100%
BM 50% 0
aGVHD
Grade I 0 3 (8%)
Grade II 6 (27%) 15 (44%)
Grade III 12 (55%) 8 (24%)
Grade IV 4 (18%) 8 (24%)
Organ
Skin 22 (100%) 13 (38%)
GI 7 (32%) 27 (79%)
Liver 2 (8%) 4 (12%)
Therapy prior to sirolimus initiation
MP 22 (100%) 34 (100%)
MMF 5 (23%) 3 (9%)
Anti-TNF 2 (6%)
Anti-IL-2 18 (82%)
Anti-CD52 2 (9%)
Sirolimus line order
Line 2 2 (9%) 29 (85%)
Line 3 10 (46%) 5 (15%)
Line 4 8 (36%) 0
Line 5 2 (9%) 0
Response
OR 20 (91%) 26 (76%)
CR 19 (86%) 15 (44%)
PR 1 (5%) 11 (32%)
NR 2 (9%) 8 (24%)
Deﬁnite control 16 (72%) 11 (32%)
cGVHD 42% 44%
Toxicity
Cytopenia 14 (64%) NA
TMA 10 (45%) 7 (21%)
Lipidemia 4 (18%) NA
Outcome
OS at 1 year 41% 44%
Death 13 (59%) 20 (59%)
aGVHD indicates acute graft-versus-host disease; RIC, reduced-intensity
conditioning; MRD, matched related donors; URD, unrelated donors; MUD,
matched unrelated donors; MMUD, mismatched unrelated donors; PBSC,
peripheral blood stem cells; BM, bone marrow; GI, gastrointestinal; MP,
methylprednisolone; MMF, mycophenolate mofetyl; TNF, tumor necrosis
factor; IL-2, interleukin-2; OR, overall response; CR, complete response; PR,
partial response; NR, no response; cGVHD, chronic graft-versus-host
disease; NA, not available; TMA, thrombotic microangiopathy; OS, overall
survival.
Table 3
Sirolimus for Refractory cGVHD
Study Jurado [62] Couriel [63]
No. of patients 47 35
HSCT
MRD 38 (81%) 20 (57%)
MUD 9 (19%) 15 (43%)
PBSC 41 (87%) 16 (46%)
BM 5 (11%) 18 (51%)
Myeloablative 28 (60%)
RIC 19 (40%)
cGVHD type
De novo 14 (30%) 6 (17%)
Quiescent 19 (40%) 16 (46%)
Progressive 14 (30%) 12 (34%)
Treatment before sirolimus
CNI 33 (70%) 35 (100%)
MMF 9 (19%)
MP 5 (11%) 35 (100%)
Other 1 (2%)
Classiﬁcation of cGVHD
Extensive 23 (66%)
Scleroderma 17 (36%) 11 (31%)
PLT < 100 19 (40%) 13 (38%)
Sirolimus administration
Loading No 6 mg day 1
Daily dose 2 mg die 2 mg die
Target level 5-10 ng/mL 7-12 ng/ml
2nd line 12 (25%) 13 (37%)
3rd line 16 (34%) 22 (63%)
4th line 13 (28%)
5th line 6 (13%)
Toxicity
Renal 14 (30%) 23 (66%)
TMA 4 (8%) 4 (11%)
Lipidemia 19 (40%) 27 (77%)
Cytopenia 12 (25%) 22 (63%)
Infection 27 (77%)
Response
OR 38 (81%) 22 (63%)
CR 18 (38%) 6 (17%)
PR 20 (43%) 16 (46%)
NR 6 (13%) 12 (34%)
NE 3 (6%) 1 (3%)
MP stopped 12 (34%)
cGVHD indicates chronic graft-versus-host disease; HSCT, hematopoietic
stem cell transplantation; MRD, matched related donors; MUD, matched
unrelated donors; PBSC, peripheral blood stem cells; BM, bone marrow; RIC,
reduced-intensity conditioning; CNI, calcineurin inhibitor; MMF, mofetyl
mycophenolate; MP, methylprednisolone; PLT, platelets; TMA, thrombotic
microangiopathy; OR, overall response; CR, complete response; PR, partial
response; NR, no response; NE, nonevaluable.
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continuing tacrolimus while maintaining sirolimus.
OS at 1 year was similar in both studies (41% to 44%).
Signiﬁcant predictors of OS included remission status at
HSCT, achievement of complete response from aGVHD with
sirolimus alone. No other characteristics were signiﬁcant
including organ involvement or GVHD grade. Mortality rate
was 59% in both studies. Hoda et al. [61] reported a relapse
rate of 15%, and an RFS of 42%. Cytopenias and hyperlipid-
emia were common but mostly mild and did not require
treatment modiﬁcation. No hepatotoxicity was observed. Not
surprisingly, infection was a common complication and was
the primary cause of death in both studies.
These 2 retrospective studies demonstrate a potential role
of sirolimus in steroid-refractory aGVHD, a condition for
which there is no standard of care, and new alternatives are
imperatively needed. The impressive overall response rate
(ORR) can be explained in part by the fact that 30% to 50% ofpatients had limited stage (grade I-II) refractory aGVHD and
more than half received sirolimus rather early in their course
as a second-line treatment. Patients treated under the Hoda
et al. [61] study received lower doses of front-line cortico-
steroids, which may have selected more favorable cases.
Surprisingly, but probably due to the small number of
patients in each subgroup, the severity or site of aGVHD had
no inﬂuence on response rate. This is in contrast with
previous studies demonstrating decreased response rates
with increased severity of aGVHD. These results are sufﬁ-
ciently provocative to deserve further investigation.THERAPY OF STEROID-REFRACTORY cGVHD
Because of its antiﬁbrotic property, it is probably for the
treatment of cGVHD that sirolimus holds its greatest pro-
mises. Despite this, sirolimus role for treatment of cGVHD
refractory to steroids is still poorly deﬁned with only 4
retrospective studies published to date. Sirolimus use in this
setting was investigated in 2 main studies conducted by
Jurado et al. [62] and Couriel et al. [63]. Another study by
Jedlickova et al. [46] investigated its speciﬁc role as a ﬁrst-
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cases and will be discussed separately.
The studies are summarized in Table 3. In both studies,
prior GVHD treatment remained the same at sirolimus initi-
ation and was tapered in case of GVHD control. ORRs ranged
from 63% to 81%, with complete resopnse rates between 17%
and 38%. Interestingly in the Jurado et al. [62] study, a loading
doseof sirolimuswasnot given,which led to the lowest serum
target levels and the highest ORR and complete response rate.
The presence of scleroderma, platelet counts <100, and type
of immunosuppressive combinations preceding sirolimus
had no inﬂuence on response rates. In the Couriel et al. [63]
study, ORR was signiﬁcantly better in skin GVHD (65%) and
with sclerodermatous features (73%). The complete response
and partial response rates according to organ involvement
were 24% and 41% for skin, 9% and 55% for eyes, 25% and 50%
for mouth, 50% and 1% for lower GI tract, and 0% and 2% for
liver. By the end of the Couriel et al. [63] study, 34% of patients
were completely tapered off steroids.
OS at 3 years was 57% in the Jurado et al. [62] study,
whereas in the Couriel et al. [63] study, it was 62% for true
cGVHD and 12% for late-onset aGVHD, at 2 years. The toxicity
proﬁle of each study is shown in Table 3. The least toxicity
was observed in the Jurado et al. [62] study, which targeted
the lowest sirolimus trough level (5-10 ng/mL).
CNI-FREE THERAPY FOR SCLERODERMATOUS cGVHD
A recent publication retrospectively studied the role of
sirolimus for treatment of sclerodermatous cGVHD [46]. This
study used sirolimus and another mTOR-inhibitor (mTOR-I),
everolimus. The study included 34 patients with NIH score 3
sclerodermatous cGVHD. Both mTOR-Is were used in the
study, initially as salvage therapy, but subsequently as front-
line treatment. The cGVHDwas progressive in 14.7%, de novo/
quiescent in 38.2%, post-DLIs in 29.4%, and post retrans-
plantation in 17.6%. All patients had variable extra cutaneous
GVHD manifestations. Sirolimus was used in 38.2%, whereas
61.8%of patients receivedeverolimus. ThemTOR-Iwasusedas
ﬁrst-line in 44.1%, as second-line in 35.3%, and as third-line
in 20.6%. A total of 35.3% of patients received sirolimus
monotherapy. The majority of patients received mTOR-I in
combination with other immunosuppressors including
steroids, MMF, and extracorporeal photopheresis (ECP). Only
1 patient was treated with a CNI (CSA).
ORR was 76%, with complete response in 17.6% and partial
response in 58.8%. Median time to partial response for all
patients was 3 months. Median time to complete response
was 223 days in the monotherapy group. A steroid-sparing
effect was observed in 26% of patients who stopped steroids
3 months after initiation of mTOR-I. At the end of follow-up,
52% had completely discontinued steroid therapy. The pro-
jected OS at 3 years was 72% with no signiﬁcant difference
observed between sirolimus and everolimus.
TMA, observed in 5.9% of patients, correlated with high
mTOR-I trough levels and resolved after dose reduction. This
incidence of TMA is particularly informative and demon-
strates that it can also occur when sirolimus is not used in
combination with CNI although at a much lesser rate and
severity. Other observed toxicities were hyperlipidemia in
20.6%, impaired wound healing in 14.7%, and thrombosis in
8.8%. No nephrotoxicitywas reported. Eight of the 34 patients
died, 5 of them from cGVHD, 1 from secondary malignancy,
1 from relapse, and 1 from unknown cause. Despite the very
high-risk population (38% underwent a second allogeneic
transplantation for relapse after the ﬁrst transplantation), allpatients but 1 remain in complete hematologic remission.
This may again suggest a concomitant antitumoral effect of
mTOR-I associated to cGVHD-mediated GVT effect.
These studies conﬁrm the efﬁciency of sirolimus in
true cGVHD treatment particularly with sclerodermatous
features. In this setting, there is no need for a loading dose at
treatment initiation. Combined modality leads to superior
and faster response, and long-term therapy (6 months) is
required to achieve the maximum effect. There is a steroid-
sparing effect associated with sirolimus treatment. This
represents a major advantage over other immunosup-
pressors considering the deleterious effect and burden of
long-term corticosteroid treatment. An ongoing randomized
phase II/III, multicenter trial is comparing sirolimus plus
prednisone, sirolimus/ECP plus prednisone, and sirolimus/
CNI plus prednisone for the treatment of cGVHD [64]. The
results of this study will help clarify the role and efﬁcacy of
sirolimus on speciﬁc organ involvement and the optimal
combination for the treatment of cGVHD.
SIROLIMUS ANTINEOPLASTIC PROPERTIES
One study conducted by Armand et al. [65] investigated
sirolimus antineoplastic activity. The study retrospectively
analyzed 190 patients who underwent transplantation for
lymphoma. The study compared the outcomes of patients
who received sirolimus, CNI, with or without low-dose MTX
for GVHD prophylaxis vs those who received CNI, MTX
without sirolimus in RIC, and myeloablative HSCT. OS was
signiﬁcantly superior in the sirolimus-treated group,
conﬁrmed by multivariate analysis and persisted after
adjustment for the occurrence of GVHD. The 3-year OS was
66% in the sirolimus group, in sharp contrast to patients not
receiving sirolimus (38%; P ¼ .007). Similarly, the 3-year
progression-free survival ratewas 44% for the sirolimus group
and 17% for the nonsirolimus group (P ¼ .001). This beneﬁt
was entirely restricted to patients undergoing RIC-HSCT.
When the authors examined the impact of sirolimus on
lymphoma subtypes, it was mostly marked for low-grade B
cell non-Hodgkin lymphoma, chronic lymphocytic leukemia,
and Hodgkin lymphoma. The clear impact of sirolimus on
disease control when used in GVHD prophylaxis and treat-
ment will remain difﬁcult to demonstrate outside well-
designed prospective randomized studies, considering the
numerous confounding factors playing on relapse risk after
allogeneic transplantation. However, the results are inte-
resting enough to motivate the development of such trials.
CONCLUSION
Sirolimus’ unique immunosuppressive activity through
T cell inhibitionwhile promoting Tregs fulﬁlls the theoretical
function of reducing anti host activity while preserving the
antitumoral effect. Its multifaceted properties explain the
growing interest for its use in HSCT. From the current existing
literature summarized in Table 4, several important points
should be underlined for the incorporation of sirolimus in the
management of GVHD. When combined to a CNI, tacrolimus
should be favored over CSA in order to beneﬁt from the
synergy and decrease the risk of TMA [5-7,66]. There seems to
be no advantage to incorporate MTX or ATG in the prophy-
lactic regimens [51]. Most reported cases of TMA were
successfully managed by CNI dose reduction. To avoid
signiﬁcant toxicities, the doses and trough levels must be
carefully prospectively monitored. The dosing commonly
used in prophylaxis is a 12-mg loading dose on day -3 fol-
lowed by a maintenance dose of 4 mg daily in order to target
Table 4
Sirolimus role in Graft-versus-Host Disease Management
Study Conditioning aGVHD
Prophylaxis
Sirolimus aGVHD
Incidence
cGVHD
Incidence
Donor
Type
TMA
Incidence
CMV
Reactivation
ORR CR PR OS RFS Relapse NRM Comments
Starting
Day
Loading
Dose
Daily
Dose
Target Level Grade
II-IV
Grade
III-IV
aGVHD prophylaxis with CNI
Retrospective (3) Tacolimus preferred
over CSA.
Rodriguez
et al. [52]
MA Sirolimus+ Day-3 12 mg 4 mg 5-10 ng/ml 43.0% 15.0% 51.0% MRD and
MUD
19.0% 25.0% 66.0% 58.0% 34.0% 10.2% No added beneﬁts of
MTX or ATG.
Cutler et al. [53] MA Tacrolimus Day-3 12 mg 4 mg 5-10 ng/ml 20.5% 4.8% 59.1% 7.0% 3.0% 72.2% 68.5% 16.2% No impact of donor
type on GVHD.
Rosenbeck
et al. [54]
MA (+/-) ATG Day-3 12 mg 4 mg 5-15 ng/ml 18.6% 5.1% 40.4% 10.2% Possible reduction of
CMV reactivation and
relapse rate.
CNI free
Retrospective (1) Excellent plateform
for immunotherapy.
Schleuning
et al. [55]
RIC
FLAMSA
Sirolimus+
MMF (+/-) ATG
Day-1 None 2 mg BID 5-10 ng/ml 22.5% 30.% MRD and
MUD
None None
Reduced
72.% 67.% 23.% 14.% Randomised trial
recommended to
conﬁrm the impact of
sirolimus on disease free
survival and relapse.
Prospective (1)
Ongoing Randomisation: MRD May conﬁrm sirolimus
advantage over mtx for
GVHD prophylaxis.
Randomised
phase III
Tacolimus+MTX May conﬁrm sirolimus
impact on GVHD.
BMT-CTN 0402 Tacrolimus +
sirolimus
May conﬁrm sirolimus
protective role on CMV
infection and relapse.
aGVHD primary treatment
Retrospective (1)
Pidala et al. [59] Tacrolimus+
MTX (91%)
6 mg 4-12 ng/ml Grade
I:13%
55.0% MRD and
URD
50.0% 56.0% 37.0% 37.0% 20.0% Alternative to ﬁrst
line corticosteroids
in selected patients.
Tacrolimus+
MMF (9%)
Grade
II: 75%
Grade
III: 13%
Grade
IV: 0%
Steroids refractory aGVHD
Retrospective (2) aGVHD
treatment
1 year
Ghez et al. [60] MP 2 mg/kg 2-4 mg/m2  5 2-4 mg 7-13 ng/ml 42.0% MRD and
URD
45.0% 91.0% 86.0% 5.0% 41.0% 59.0% Potential role of
sirolimus in
corticosteroid
refractory aGVHD.
Hoda et al. [61] MP 1 mg/kg 6 mg  1 day 1-2 mg 4-12 ng/ml 44.0% 21.0% 76.0% 44.0% 32.0% 44.0% 42.0% 15.0% 59.0% Severity and site of
aGVHD had no impact
on response rate.
cGVHD treatment
Retrospective (2)
Jurado et al. [62] None 2 mg 5-10 ng/ml MRD and
MUD
8.0% 81.0% 38.0% 57.0% Loading dose of
sirolimus not required
in cGVHD treatment.
Couriel et al. [63] 6 mg  1 day 2 mg 7-12 ng/ml 11.0% 63.0% 17.0% 62.0% High response rate in
true cGVHD.
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should be initiated on dayþ100. There seems to be no impact
on cGVHD incidence, and a reduced incidence of CMV reac-
tivation has been suggested by some studies [53,55,66].
Sirolimus antineoplastic activity has been observed in
several studies, mostly after RIC transplantations [46,55,65].
The literature available seems to support a beneﬁt of siroli-
mus’ antineoplastic activity when incorporated in GVHD
prophylaxis regimens in the RIC setting, whereas patients
receiving dose-intense myeloablative conditioning may not
derive any additional antitumor beneﬁts [65].
The role of sirolimus in an CNI-free GVHD prophylactic
regimen seems particularly promising [55]. It demonstrated
lower grade II to IV aGVHD incidence (22.5%) and compa-
rable de novo cGVHD incidence (30%). The low relapse inci-
dence may suggest an antileukemic activity of sirolimus.
Furthermore, the sirolimus/MMF combination seemed to
provide an excellent platform for adjuvant immunotherapy.
Finally, the toxicity proﬁle of sirolimus in the absence of CNI
is improved with reduced CMV reactivation and minimal
renal impairment, TMA, and VOD.
Although only one single retrospective study investigated
sirolimus as ﬁrst-line therapy for aGVHD [59], it provides
some clues to its potential use in limited-stage aGVHD.
Sirolimus demonstrated comparable complete response
rates (50%) to glucocorticoids (59%; P ¼ .47). It also demon-
strated sirolimus’ steroid-sparing effects. However, the time
to response is longer when compared to glucocorticoids.
Sirolimus as a substitute to ﬁrst-line glucocorticoid therapy
for aGVHD represents an attractive option particularly when
steroids are contraindicated. In the event of sirolimus failure
as primary therapy, addition of glucocorticoids at a reduced
dose of 0.5 to 1 mg/kg may be sufﬁcient. Furthermore, siro-
limus may have a role for initial concomitant use with lower
glucocorticoids dose in selected patients.
When sirolimus is considered for treatment of steroid-
refractory aGVHD, it is usually combined with a CNI
[60,61,67]. A loading dose seems beneﬁcial leading to supe-
rior response. We do recommend initial therapy duration of
at least 2 weeks, because the median time to response is 8
days [60], and patients who failed to complete 14 days do not
achieve complete response [67]. Responses are not signiﬁ-
cantly different among all GVHD grades and organ involve-
ment. GVHD ﬂares after sirolimus taper seems to respond to
reinitiation of sirolimus. Again, sirolimus demonstrates
successful steroid-sparing effects [61]. Finally, in view of the
absence of clear guidelines for treatment of steroid refractory
aGVHD, we believe that the use of sirolimus should be
considered earlier and further investigated.
The role of sirolimus in cGVHD treatment represents
a special interest due to its pro-Tregs [15,16] and antiﬁbrotic
[19,20] activities of great potential in sclerodermatous GVHD
andbronchiolitis obliterans. In combinationwithCNIs, theORR
was reported between 63% and 81% andOS at 3 years between
57 and 72% [62,63,67]. There seems to be no beneﬁt associated
with loading doses of sirolimus in patients with cGVHD, and
the most commonly used maintenance dose is 2 mg/day.
The ongoing phase III BMT CTN trial [64] is estimated to
ﬁnish by March 2019. Until then, sirolimus represents an
appealing option for steroid-refractory cGVHD. It should be
prioritized for cases with sclerodermatous forms and bron-
chiolitis obliterans and may be considered as ﬁrst-line treat-
ment in combination with steroids for these manifestations.
We do support using a CNI-free sirolimus combination for
cGVHD to optimize sirolimus pro-Tregs activity [68].
A. Abouelnasr et al. / Biol Blood Marrow Transplant 19 (2013) 12e2120In conclusion, sirolimus is now becoming an extremely
valid option for the management of GVHD, whether for
prophylaxis or treatment. Despite the current interest and
theoretical advantages over other immunosuppressive drugs,
manyquestions regarding its optimal use remainunanswered
(Table 4). More evidence is expected to emerge in the near
future from the ongoing studies. These studies will further
deﬁne the optimal use of sirolimus in allogeneicHSCTand the
standard of care for GVHD management.
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